DDX53 and neoplasm: We next investigated the antitumoral activity of biNV-IL-15 in different tumor models (4T1 (Fig. 5a), CT26 (Supplementary Fig. 8a), and B16F10-OVA (Fig. 6a)) to assess the adaptability and flexibility of biomimetic nanovaccine-mediated spatiotemporal integration of multivalent IL-15 self-transpresentation and tumor antigen presentation.